Research bodies and industry should combine efforts to develop biomarkers for dementia
BMJ 2008; 337 doi: https://doi.org/10.1136/bmj.a2258 (Published 24 October 2008) Cite this as: BMJ 2008;337:a2258- Anne Gulland
- 1London
A report on mental health has called for medical research bodies and the drug industry to join forces to find biomarkers for the early identification of dementia.
The study, Mental Capital and Wellbeing, says that biomarkers are vital for the prompt detection and monitoring of dementia. Biomarkers are objective biological measures associated with the presence of a disease, increased risk, or response to treatment.
The report, published by Foresight, part of the Government Office for Science, aims to advise the government on how to achieve the best possible mental development and mental wellbeing in …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.